Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Regulatory
Approvals worldwideDrug spendingDrug targets
Regulatory · NICE technology appraisal guidance · England

NICE technology appraisals

Every medicine and treatment NICE has appraised for the NHS in England since 2000: NICE's recommendation, when it was published, whether it still stands, and a link to the guidance and to the medicine's trials on this site.

Source: NICE technology appraisal guidance and NICE's appraisal recommendations data, shown with NICE's permission. Checked 3 Oct 2026
1,189Technology appraisals published
90%Of 897 current decided appraisals recommend for at least some patients
72Published in 2026 so far
976Linked to a medicine page here
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from NICE technology appraisal guidance · Last verified · Editorial standards

NICE has published 1,189 technology appraisals since 2000, and 1,062 of them are still current. Of the current appraisals where NICE reached a decision, 90% recommend the medicine or treatment for at least some patients, including through the Cancer Drugs Fund. The most recent is TA1189, published 26 Aug 2026. NICE's decisions apply to the NHS in England; in Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics.

01

What NICE decided

Appraisals by recommendation type
Recommended or optimised
836
Cancer Drugs Fund or Innovative Medicines Fund
64
Only in research
23
Not recommended
145
Terminated (no company submission)
177

An appraisal can contain several recommendations, for different groups of patients, so it can appear under more than one type. These explanations are ours; NICE's own definitions are on nice.org.uk.

02

Cancer Drugs Fund or Innovative Medicines Fund

64 appraisals, newest first
AppraisalMedicine pageNICE recommendationPublishedStatus
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer
NICE TA1158
AmivantamabRecommended (Cancer Drugs Fund)28 May 2026Current
Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over
NICE TA1044
—Optimised (Innovative Medicines Fund)26 Feb 2025Current
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
NICE TA1023
ElranatamabOptimised (Cancer Drugs Fund)11 Dec 2024Current
Belzutifan for treating tumours associated with von Hippel-Lindau disease
NICE TA1011
BelzutifanRecommended (Cancer Drugs Fund)16 Oct 2024Current
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over
NICE TA1003
—Recommended (Innovative Medicines Fund)11 Sep 2024Current
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B
NICE TA989
—Optimised (Innovative Medicines Fund)24 Jul 2024Current
Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA963
DostarlimabRecommended (Cancer Drugs Fund)3 Apr 2024Replaced by TA1064
Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
NICE TA911
SelpercatinibOptimised (Cancer Drugs Fund)26 Jul 2023Current
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
NICE TA895
Axicabtagene CiloleucelRecommended (Cancer Drugs Fund)7 Jun 2023Current
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over
NICE TA893
—Recommended (Cancer Drugs Fund)7 Jun 2023Current
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer
NICE TA885
PembrolizumabRecommended (Cancer Drugs Fund)3 May 2023Replaced by TA939
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
NICE TA862
Trastuzumab deruxtecanRecommended (Cancer Drugs Fund)1 Feb 2023Current
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
NICE TA823
AtezolizumabRecommended (Cancer Drugs Fund)28 Sep 2022Replaced by TA1071
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
NICE TA781
SotorasibRecommended (Cancer Drugs Fund)30 Mar 2022Current
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
NICE TA779
DostarlimabRecommended (Cancer Drugs Fund)16 Mar 2022Current
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection
NICE TA761
OsimertinibOptimised (Cancer Drugs Fund)19 Jan 2022Current
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer
NICE TA760
SelpercatinibRecommended (Cancer Drugs Fund)12 Jan 2022Current
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
NICE TA756
FedratinibRecommended (Cancer Drugs Fund)16 Dec 2021Current
Selpercatinib for treating advanced thyroid cancer with RET alterations
NICE TA742
SelpercatinibRecommended (Cancer Drugs Fund)3 Nov 2021Replaced by TA1038
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
NICE TA704
Trastuzumab deruxtecanRecommended (Cancer Drugs Fund)26 May 2021Current
Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer
NICE TA693
OlaparibOptimised (Cancer Drugs Fund)28 Apr 2021Replaced by TA946
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma
NICE TA677
—Recommended (Cancer Drugs Fund)24 Feb 2021Current
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA673
NiraparibRecommended (Cancer Drugs Fund)17 Feb 2021Current
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia
NICE TA663
VenetoclaxOptimised Recommended (Cancer Drugs Fund)9 Dec 2020Current
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
NICE TA658
IsatuximabRecommended (Cancer Drugs Fund)18 Nov 2020Current
Avelumab with axitinib for untreated advanced renal cell carcinoma
NICE TA645
AvelumabRecommended (Cancer Drugs Fund)2 Sep 2020Replaced by TA1120
Entrectinib for treating NTRK fusion-positive solid tumours
NICE TA644
EntrectinibRecommended (Cancer Drugs Fund)12 Aug 2020Replaced by TA1118
Larotrectinib for treating NTRK fusion-positive solid tumours
NICE TA630
LarotrectinibRecommended (Cancer Drugs Fund)27 May 2020Current
Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA620
OlaparibOptimised Optimised (Cancer Drugs Fund)15 Jan 2020Replaced by TA908
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA619
PalbociclibRecommended (Cancer Drugs Fund)15 Jan 2020Replaced by TA836
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA611
RucaparibRecommended (Cancer Drugs Fund)13 Nov 2019Current
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA600
PembrolizumabRecommended (Cancer Drugs Fund)11 Sep 2019Current
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA598
OlaparibRecommended (Cancer Drugs Fund)28 Aug 2019Replaced by TA962
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA593
RibociclibOptimised (Cancer Drugs Fund)14 Aug 2019Replaced by TA687
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
NICE TA592
CemiplimabRecommended (Cancer Drugs Fund)7 Aug 2019Current
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA581
NivolumabRecommended (Cancer Drugs Fund)15 May 2019Replaced by TA780
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA579
AbemaciclibRecommended (Cancer Drugs Fund)8 May 2019Replaced
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA578
DurvalumabRecommended (Cancer Drugs Fund)1 May 2019Current
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
NICE TA573
DaratumumabRecommended (Cancer Drugs Fund)10 Apr 2019Replaced by TA897
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
NICE TA567
TisagenlecleucelRecommended (Cancer Drugs Fund)13 Mar 2019Replaced by TA933
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies
NICE TA559
Axicabtagene CiloleucelRecommended (Cancer Drugs Fund)23 Jan 2019Current
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
NICE TA558
NivolumabRecommended (Cancer Drugs Fund)23 Jan 2019Replaced by TA684
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer
NICE TA557
PembrolizumabOptimised (Cancer Drugs Fund)10 Jan 2019Replaced by TA683
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
NICE TA554
TisagenlecleucelRecommended (Cancer Drugs Fund)21 Dec 2018Replaced by TA975
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
NICE TA553
PembrolizumabRecommended (Cancer Drugs Fund)19 Dec 2018Current
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
NICE TA540
PembrolizumabOptimised (Cancer Drugs Fund)3 Sep 2018
Updated 1 May 2024
Current
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
NICE TA529
CrizotinibRecommended (Cancer Drugs Fund)4 Jul 2018Current
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
NICE TA528
NiraparibOptimised (Cancer Drugs Fund)4 Jul 2018Replaced by TA784
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA522
PembrolizumabRecommended (Cancer Drugs Fund)13 Jun 2018Current
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
NICE TA519
PembrolizumabRecommended (Cancer Drugs Fund)25 Apr 2018Replaced by TA692
Avelumab for treating metastatic Merkel cell carcinoma
NICE TA517
AvelumabRecommended Recommended (Cancer Drugs Fund)11 Apr 2018
Updated 21 Apr 2021
Current
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
NICE TA510
DaratumumabOptimised (Cancer Drugs Fund)14 Mar 2018Current
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
NICE TA505
IxazomibOptimised (Cancer Drugs Fund)7 Feb 2018Current
Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
NICE TA492
AtezolizumabRecommended (Cancer Drugs Fund)6 Dec 2017Replaced by TA739
Ibrutinib for treating Waldenstrom’s macroglobulinaemia
NICE TA491
IbrutinibRecommended (Cancer Drugs Fund)22 Nov 2017Replaced by TA795
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
NICE TA490
NivolumabRecommended (Cancer Drugs Fund)22 Nov 2017Current
Venetoclax for treating chronic lymphocytic leukaemia
NICE TA487
VenetoclaxRecommended (Cancer Drugs Fund)8 Nov 2017Replaced by TA796
Nivolumab for previously treated non-squamous non-small-cell lung cancer
NICE TA484
NivolumabRecommended (Cancer Drugs Fund)1 Nov 2017Current
Nivolumab for previously treated squamous non-small-cell lung cancer
NICE TA483
NivolumabRecommended (Cancer Drugs Fund)1 Nov 2017Current
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
NICE TA472
ObinutuzumabRecommended (Cancer Drugs Fund)30 Aug 2017Replaced by TA629
Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
NICE TA465
—Recommended (Cancer Drugs Fund)9 Aug 2017Withdrawn
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
NICE TA447
PembrolizumabOptimised (Cancer Drugs Fund)28 Jun 2017Current
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
NICE TA446
Brentuximab VedotinOptimised Optimised (Cancer Drugs Fund)28 Jun 2017Current
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
NICE TA416
OsimertinibRecommended (Cancer Drugs Fund)26 Oct 2016Current

Titles link to the guidance on nice.org.uk, where the full recommendations are. A medicine is linked to its page here only when the name NICE appraised is exactly the same molecule as ours; medicines given alongside it (“with chemotherapy”) are not counted as appraised. Appraisals of devices and procedures are listed but have no medicine page.

© NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Medicines data, weekly

One email every Friday: new approvals, trials and shortages, with every figure linked to its source.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

NICE has allowed us to show the appraisal number, title, recommendation category and dates of each technology appraisal, with a link to the guidance. No guidance text is reproduced.

A nightly job reads NICE's recommendations data, reads each new appraisal page once and re-checks every page every 60 days for replaced or withdrawn guidance. It keeps the previous version if a refresh fails. No AI drafting. See our methodology. The NICE data on this page was last retrieved on 3 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.